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 Kidney transplantation is the treatment of choice for 
chronic end-stage renal disease, offering greater survival 
when compared to dialysis.1 The gap between the number of 
patients and available organs has been steadily increasing.2 
Currently there is no international consensus on the factors 
that should be considered in the kidney allocation process. 
The major debate in the allocation of scarce donor organs 
centers on the competing ethical values of utility (maximum 
outcomes) and equity (fairness).3 The current Portuguese 
criteria for allocation include criteria to satisfy both these 
principles: candidates’ waiting time on dialysis and state of 
hypersensitization for fairness; and maximization of human 
leukocyte antigen (HLA) compatibility, and age differential 
between donor and recipient for utility. When this allocation 
system was introduced, in 2007, one of its main objectives 
was to mitigate the disadvantage of hypersensitized 
patients who were subjected to disproportionately longer 
waiting times.4 Ten years later, it is now time to evaluate its 
outcomes and introduce changes for improvement in light of 
new clinical data.
 Research such as the article “Donor-recipient pair 
selection in renal transplantation: comparative results 
from a simulation”5 published in this edition of Acta 
Médica Portuguesa, constitutes an invaluable landmark 
for future deliberations. This article results from years 
of investigation led by the authors and has the merit of 
simulating the application of a new allocation model.3 In 
the authors’ proposal organs are distributed among four 
groups of candidates stratified by time on dialysis and 
hypersensitization status. Each group is assigned a color: 
red (clinical urgency), orange (calculated panel reactive 
antibody (cPRA) ≥ 85% or dialysis time greater than the 
3rd quartile, i.e. dialysis time required until 75% of the 
candidates on the waiting list are transplanted), yellow 
(cPRA ≥ 50% or with a dialysis time greater than the 
median of dialysis time required until transplantation), and 
lastly, green (encompassing the remaining candidates). In 
this proposal clinical urgency is the top priority. While many 
allocation systems do not include medical urgency as a 
criteria, it seems important to recognize that not all patients 
can afford to wait the same amount of time.3
 The proposed color priority system improves 
transparency by rendering allocation more intelligible to 
patients, and addresses one of the most criticized aspects 
of current allocation systems: waiting time on dialysis as the 
primary driver of allocation.6 The authors’ results suggest 
that the mere reduction of the scoring currently attributed 
to dialysis time (0.1 points per month) may be insufficient 
to produce appreciable benefits. Another positive change 
proposed is the definition of hypersensitization according 
to calculated panel reactive antibody (PRA) cPRA, instead 
of PRA by complement-dependent cytotoxicity. The later 
method unfairly disadvantages hypersensitized candidates, 
by increasing their waiting time unduly.7 Use of cPRA 
for allocation purposes has already been successfully 
implemented in other countries.8
 Having based their simulation on data concerning only 
HLA genotype distribution of the Portuguese northern 
population, the authors recognize that it is only possible 
to estimate the likelihood of obtaining a compatible organ 
for a specific recipient if national HLA data is available, 
which is still not the current practice.9 In the near future HLA 
matching is expected to be determined at the epitope level. 
This will allow identification of more suitably mismatched 
donors for non-sensitized patients, as well as, acceptable 
mismatches for sensitized transplant candidates.10
 Nonetheless, there is a general trend toward a reduction 
in the influence of HLA mismatch and an increase in the 
importance of other factors shown to affect the longevity 
mismatch of organs and recipients.3 The new allocation 
system introduced in the United States (USA) in 2014 
allows for a reasonable estimation of recipient’s survival 
and graft longevity, and preferentially allocates kidneys with 
longer expected duration of function to patients expected 
to live longer.11 In the USA, prediction of graft survival 
was shown to be significantly improved when considering 
donor comorbidities (hypertension, diabetes, etc) in 
addition to age alone.11,12 In their simulation the authors 
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propose an old-to-old allocation, similar to that implemented 
by Eurotransplant, which has presented satisfactory 
results.13
 Allocation systems are subject to permanent reform 
worldwide. Other options currently being discussed include 
use of hepatitis C virus infected donors, and marginal grafts 
with a favorable pathology examination.14,15 Some countries 
have also opted to give priority to patients who have 
previously donated a kidney.16 Countries with geographic 
size similar to Portugal, such as Israel, have opted to 
allocate organs only at a national level, without any local or 
regional priority. In allocation systems where this has been 
implemented, access for disadvantaged patient groups 
has improved, especially for hypersensitized patients.17 
However, national shipping of kidneys may create logistical 
challenges and may increase cold ischemic time, and 
delayed graft function, as seen in the United States.6,17 
Other strategies to expand the donor pool have consisted 
on the use of kidneys retrieved after cardiac death. This that 
was been legally established in 2013 has yet to achieve 
its full potential, with only a limited number of transplant 
centers currently performing it.
 The implementation of new measures regarding kidney 
allocation will necessarily affect the current balance between 
efficiency and fair access. Therefore vigilant monitoring and 
critical assessment of the outcomes will be necessary from 
the kidney transplant community as potential consequences 
could include reduction in transplant rates for specific patient 
groups.18 Despite their inherent limitations, simulations 
remain the best method to predict future changes.
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